From £6.99 per month
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares


Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Results: AVO

Search articles by EPIC code

At what point does Daddy Pig’s compliance officer put a stop to the Advanced Oncotherapy farce?

I do not believe that Advanced Oncotherapy (AVO) will ever generate a cent of positive free cashflow as the demand for the proton therapy services it will offer at some point in 2023 is, in my view, already fully catered for with existing capacity. Others, notably a fund management firm run by a chap who looks remarkably like Daddy Pig, father of Peppa, disagree but what we might agree on its that, until late 2023, there is no doubt that Advanced will continue to guzzle cash. Which makes the next bailout placing only a matter of time.


Advanced Oncotherapy – Yet Another Fundraise As Odey Doubles Down Again

AIM-listed Advanced Oncotherapy (AVO) has announced yet another fundraise – this time for £6 million (before expenses) for the issue of another 24 million bits of confetti and associated warrants at 25p – the par price of the shares (below which it is not permitted to issue stock). The grateful recipient of the latest round of paper? Step forward clients of Odey Asset Management as Crispin Odey’s outfit doubles down yet again.


Advanced Oncotherapy – Has It Broken AIM Rule 11 and missed another deadline?

The end of August is generally regarded as the end of summer here in the UK, but the official date for the beginning of autumn is actually September 23 for this year. It is a moot point for most, but not so for AIM-listed Advanced Oncotherapy (AVO) – which had been promising that its first LIGHT medical proton bean unit would be up and running by the end of the summer.


Advanced Oncotherapy’s latest fund raise, this is just taking the piss

The real problem Advanced Oncotherapy (AVO) faces, as I explained here, is that there is not enough demand for its Harley Street proton centre to make a profit even when its LIGHT system is up and running. But for now, LIGHT is not up and running, the company is guzzling cash and that brings us to today’s latest keep the LIGHTs on fund raise. Advance really is taking the piss with its excuses.


Advanced Oncotherapy is a slam dunk short

I should declare that I am a shareholder in this company. I bought 1 share a few years ago so that I could attend its AGM to quiz the management on the catalogue of lies they had told to investors.  Then covid struck. On a properly regulated market Advanced Oncotherapy (AVO) would have been given the order of the boot years ago, but this is AIM.


Advanced Oncotherapy – Has Odey Doubled Down In Face Of Embarrassment Of Insolvency?

AIM-listed Advanced Oncotherapy (AVO) has announced that Odey Asset Management is coughing up another £4.5 million as part of a £6 million fundraise to add to its investment in March of £2 million, again at 25p a pop – the par price. So is this an act of faith by Odey, or a case of if you owe the bank a million quid then it is the bank which has a problem?

Page 1 of 26 (257 articles)
Subscribe to our newsletter

Daily digest of our latest stories.

Search ShareProphets

Complete Coverage

Recent Comments